Clinical trials: Pneumococcal Conjugate Vaccine
Pneumococcal Vaccines
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar.
- Trial name
- NCT00824655
- Testing
- 13vPnC
- Where
- 7 sites in Sweden
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Pfizer
Herpes Zoster, Pneumococcal Infection
ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are…
- Trial name
- NCT00535730
- Testing
- Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™, Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in children aged 2 Months (Minimum 6 Weeks) to 17 Years .
- Trial name
- NCT06675032
- Testing
- PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Streptococcal Infections
A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine
Three dose primary vaccination with 11-valent pneumococcal conjugate vaccine administered concomitantly with Infanrix™ hexa to healthy infants between 8 to 16 weeks of age at the time of first vaccination.
- Trial name
- NCT00169481
- Testing
- Pneumococcal (vaccine)
- Where
- 56 sites in Germany
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07629440
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 130 sites in United States, Japan and 1 more
- Volunteers
- 3,230 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis B
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6…
- Trial name
- NCT02610348
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
- Trial name
- NCT00334334
- Testing
- Pneumococcal (vaccine)
- Where
- 66 sites in Germany, Poland and 1 more
- Volunteers
- 1,572 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
Primary Objective: To evaluate the impact of PCV7 vaccination on NP carriage rate of vaccine serotypes and serotype distribution Secondary Objective: To evaluate the impact of PCV7 vaccination on NP carriage of antibiotic…
- Trial name
- NCT00488371
- Testing
- Pneumococcal Conjugated Vaccine (Prevnar®)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neisseria Meningitidis, Haemophilus Influenzae Type b
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
This protocol posting deals with objectives \& outcome measures of an extension phase when subjects are aged 3, 4 and 6 years of age.
- Trial name
- NCT00891176
- Testing
- MenitorixTM, Pneumococcal conjugate vaccine GSK1024850A, PrevenarTM
- Where
- 28 sites in Germany, Poland and 1 more
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcus Pneumoniae Vaccines
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis.
- Trial name
- NCT00307008
- Testing
- Pneumovax 23™
- Where
- 5 sites in Sweden
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan
- Trial name
- NCT04875533
- Testing
- 20vPnC, Saline, 13vPnC
- Where
- 28 sites in Japan, South Korea and 1 more
- Volunteers
- 1,425 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
The purpose of this study is to evaluate the safety and immunogenicity of LBVE013 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) or LBVE014 (Pneumococcal 14-valent conjugate vaccine [diphtheria CRM197…
- Trial name
- NCT02892812
- Testing
- Pneumococcal conjugate vaccine
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Streptococcus Pneumoniae
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
GEN-004 is a combination of 3 conserved proteins from Streptococcus pneumoniae. This is a randomized, double-blind, placebo-controlled, dose escalation study.
- Trial name
- NCT01995617
- Testing
- GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Pneumonia, Pneumococcal
Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months
The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT04108845
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Infections, Streptococcal
Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose
This primary purpose of this study is the evaluation of the immunological persistence following completion of the 3-dose primary vaccination course with either a clinical or a commercial lot of pneumococcal conjugate vaccine…
- Trial name
- NCT01119625
- Testing
- Pneumococcal vaccine GSK1024850A, Infanrix-IPV/Hib
- Where
- 3 sites in Singapore
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given…
- Trial name
- NCT00366340
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 51 sites in Germany
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
- Trial name
- NCT04379713
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 97 sites in United States, Argentina and 9 more
- Volunteers
- 1,511 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Pneumococcal Infections
A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)
The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.
- Trial name
- NCT00127153
- Testing
- V110, pneumococcal vaccine polyvalent
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Subjects will be randomly assigned to 1 of 2 groups to receive the following vaccines: Group 1: 7-valent pneumococcal conjugate vaccine (7vPnC) and diphtheria, tetanus, and accelular pertussis vaccine (DTaP), Group 2: DTaP alone.
- Trial name
- NCT01250756
- Testing
- 7-pneumococcal conjugate vaccine (7vPnC), diphtheria, tetanus, and acellular pertussis vaccine (DTaP), DTaP
- Where
- 18 sites in Japan
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Plaque Psoriasis
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic…
- Trial name
- NCT00493324
- Testing
- alefacept, polyvalent pneumococcal vaccine
- Where
- 7 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma Inc